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Abstract
Background: Type 2 diabetes mellitus is a major health threat worldwide. Cosmos caudatus is one of the medicinal
plants used to treat type 2 diabetes. Therefore, this study aims to determine the effectiveness and safety of C.
caudatus in patients with type 2 diabetes. Metabolomic approach will be carried out to compare the metabolite
profiles between C. Caudatus treated diabetic patients and diabetic controls.
Methods and design: This is a single-center, randomized, controlled, two-arm parallel design clinical trial that will
be carried out in a tertiary hospital in Malaysia. In this study, 100 patients diagnosed with type 2 diabetes will be
enrolled. Diabetic patients who meet the eligibility criteria will be randomly allocated to two groups, which are
diabetic C. caudatus treated(U) group and diabetic control (C) group. Primary and secondary outcomes will be
measured at baseline, 4, 8, and 12 weeks. The serum and urine metabolome of both groups will be examined using
proton NMR spectroscopy.
Discussion: The study will be the first randomized controlled trial to assess whether C. caudatus can confer
beneficial effect in patients with type 2 diabetes. The results of this trial will provide clinical evidence on the
effectiveness and safety of C. caudatus in patients with type 2 diabetes.
Trial registration: ClinicalTrials.gov identifier: NCT02322268
Keywords: Cosmos caudatus, Type 2 diabetes mellitus, Glycemic status, Metabolomic, Herbal medicine, Functional
food, Dietary Supplementation, Randomized controlled trial
Background
Type 2 diabetes mellitus is one of the biggest health con-
cerns in the world. In 2014, about 387 millions of people
suffer from type 2 diabetes worldwide. The number is
projected to rise to 592 million people by 2035 [1]. The
prevalence of type 2 diabetes in Malaysia showed the
same worrying trend. One in every five Malaysians age
over 30 has type 2 diabetes [2]. Despite the drug pre-
scription, a majority (78 %) of patients with type 2 dia-
betes in Malaysia still have poor glycemic control with
mean HbA1C of 8.7 % [3]. Poor glycemic control is asso-
ciated with an increased risk of diabetic microvascular
complications including neuropathy, nephropathy and
retinopathy, and macrovascular complications such as
coronary heart disease [4].
Currently, the most common treatment for type 2
diabetes includes the prescription of oral anti-diabetic
drugs such as metformin and sulphonylureas [5].
While the efficacy of sulphonylureas has been con-
firmed, their use is associated with side effects such as
increased weight gain and elevated risk of hypoglycemia
[6]. In addition, researchers have shown that long-term
treatment with oral anti-diabetic drugs is ineffective in
protecting the declining function of the pancreatic beta-
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cell [7, 8]. The deterioration of pancreatic beta-cell
function is associated with the elevated oxidative stress
in type 2 diabetic patients [9, 10]. Research indicated
that oxidative damage was higher in patients with type 2
diabetes than healthy individuals [11]. Patients with type
2 diabetes had lower antioxidant capacity than healthy
individuals [12]. Antioxidant potentially reduces the
harmful effect of oxidative stress and consequently de-
creases the insulin resistance [13].
Medicinal plants have been used as traditional medi-
cine for treating diseases, and their uses are considered
safer than the oral anti-diabetic drugs [14]. The discov-
ery of metformin, from the Galega officinalis has aug-
mented the interest to quest for more natural products
to treat diabetes [15]. Cosmos caudatus, or known lo-
cally as Ulam Raja, is a medicinal herb found in tropical
countries [16]. It has been identified as one of the ten
commonly used medicinal plants in Malaysia for treat-
ment of type 2 diabetes [17]. C. caudatus contained a
variety of bioactive compounds, such as ascorbic acid,
quercetin, proanthocyanidin, chlorogenic acid and cat-
echin [18–21]. C. caudatus has been reported to have an
extremely high antioxidant capacity of about 2500 mg
ascorbic acid equivalent antioxidant capacity (AEAC)
per 100 g of fresh samples as compared to orange and
guava which had 142 mg and 270 mg AEAC, respect-
ively [22]. Its high antioxidant content may suggest its
potential in reducing the oxidative stress [20].
In addition, C. caudatus have been shown to possess
various medicinal benefits [16] including anti-diabetic
[23], antihypertensive [24] and anti-inflammatory effect
[25] in animal studies. Recent pre-clinical study in rats in-
dicated a significantly reduction in fasting blood glucose,
and a significant improvement in lipid profile after 4 weeks
of supplementation [23]. Preliminary study in healthy vol-
unteers has shown that there was a steady reduction in
the postprandial blood glucose after consuming rice and
fresh C. caudatus (unpublished data). However, the effect
of C. caudatus in patients with type 2 diabetes remains
unclear.
Metabolomics is an unbiased approach to measure
metabolites disturbance within a biological system at a
given time [26]. The profiling of these metabolite can
provide detailed information on the metabolic pathways
[27]. Additionally, metabolites levels are influenced by
environmental factors such as diet and lifestyle factors
[28]. Therefore, by using metabolomics approach, it pro-
vides a clearer understanding of the effect of C. caudatus
in patients with type 2 diabetes.
The objective of this trial is to investigate the effective-
ness and safety of C. caudatus in patients with type 2
diabetes by addressing the following hypothesis (1) C.
caudatus supplementation will improve the glycemic
status in patients with type 2 diabetes (2) C. caudatus
supplementation will improve inflammation marker, oxi-
dative stress marker and lipid profile in patients with
type 2 diabetes (3) C. caudatus supplementation is safe
and will not result in adverse effects (4) the therapeutic
effect of C. caudatus will result in changes in urine and
serum metabolome.
Methods and design
Trial design
This is a single center, randomized, parallel-controlled
clinical trial. A flow chart of the study protocol is shown
in Fig. 1. This study will be conducted at a tertiary gov-
ernment hospital, Malaysia.
Ethical approval
The study protocol has been approved by the Ethics
Committee for Research involving Human Subjects Uni-
versiti Putra Malaysia (JKEUPM) (FPSK_Ogos (13)05),
Herbal Medicine Research Centre, Institute for Medical
Research Malaysia (version 1, 8/2014) and Medical Re-
search and Ethics Committee Ministry of Health
Malaysia (NMRR-13-1344-18177). This protocol will be
conducted in compliance with Helsinki declaration.
Randomization
Patients with type 2 diabetes will be randomly allocated
to either C. caudatus (U) group or control (C) group.
The permuted block randomization (block of 4 and 6)
will be used in this study. However, researchers will be
blinded to the size of each block to reduce the selection
bias. All laboratory personnel will also blinded to the
group allocation.
Sample size
A total of 50 patients are required in each group to de-
tect a significant mean difference of 1 % HbA1C [29],
1.75 % standard deviation [29], 95 % confidence level
and 80 % power, with additional drop-out rate of 30 %.
Study population
Patients with type 2 diabetes will be recruited from the
outpatient medical clinic at tertiary hospital. The diagno-
sis of diabetes will be based on the medical record of the
tertiary hospital. Eligible diabetic patients will be en-
rolled in the study and written informed consent will be
obtained prior to recruitment at the medical clinic of the
tertiary hospital.
Inclusion criteria
Men and women between the age of 30–65 years old who
have confirmed diagnosis of type 2 diabetes for more than
6 months, last HbA1C value greater than 7 %, Body Mass
Index (BMI) between 18.5 and 40 kg/m2, treated with sta-
bilized dose of oral anti-diabetic drugs and expected to
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Fig. 1 Trial flow chart
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remain on this oral anti-diabetic drugs throughout the
duration of the study.
Exclusion criteria
Patients with any of the following criteria will be ex-
cluded: 1) pregnant and lactating; 2) have any gastro-
intestinal disorder that interferes the bowel function,
severe hepatic or renal disease (dialysis), an infection
that requires antibiotics within three weeks; 3) on insu-
lin regimen; 4) Individuals on the anticoagulant drugs
such as warfarin and aspirin.
Intervention
Diabetic C. caudatus treated (U) group
The C. caudatus seeds were obtained from the Institute
of Bioscience, Universiti Putra Malaysia (UPM) and
planted at the Universiti Putra Malaysia Agricultural
Park. A voucher specimen (No. SK 2400/14) has been
deposited in the herbarium, Biodiversity Unit, Institute
of Bioscience, Universiti Putra Malaysia. Fresh C. cauda-
tus will be provided to the C. caudatus treated (U) group
twice a week for 8 weeks. The C. caudatus will be vac-
uum packed in a zip-lock bag before distribution. Pa-
tients in C. caudatus treated (U) group will be asked to
consume raw C. caudatus leaves (15 g) daily together
with one of the main meal (either lunch or dinner) for
8 weeks.
C. caudatus supplementation will be given simultan-
eously with the usual diabetes care that includes main-
tenance of the oral anti-diabetic drugs dosage and
compliance with the dietary and physical activity recom-
mendations. In addition, patients in C. caudatus treated
(U) group will be advised to perform self-monitoring
blood glucose. Glucometer and strips will be given to
the patients to record three values daily (after fasting,
before a meal and two hours after a meal). All the pa-
tients will be educated on how to use the glucometer.
Diabetic control (C) group
The diabetic control (C) group will be asked to abstain
from consuming C. caudatus for 8 weeks . Both groups
will be given standard lifestyle interventions which in-
clude medical nutrition therapy and physical activity en-
forcement). In addition, both groups will be educated for
the concepts of carbohydrate exchange and serving sizes.
Patients in diabetic control (C) group will be encouraged
to eat the same serving of fruits and vegetable as the C.
caudatus treated (U) group. Likewise, patients in dia-
betic control (C) group will be advised to perform self-
monitoring blood glucose. Glucometer and strips will be
given to both groups to record three values daily (after
fasting, before a meal and two hours after a meal). All
the patients will be educated on how to use the
glucometer.
Adherence
To check patients’ compliance during the 8 weeks, the
researcher will interview them weekly by telephone. In
C. caudatus treated (U) group, patients will be inter-
viewed to discern whether they were consuming C.
caudatus and to address all their concerns. In diabetic
control (C) group, phone calls are made weekly to
emphasize the importance of lifestyle modification.
Patient safety
Patients will be monitored weekly during the study
period and all the occurrence of the adverse events will
be assessed by patient interviews. All anticipated adverse
events such as loose stools, abdominal discomfort, bloat-
ing, flatulence, sign of hypoglycemia, sign of hypergly-
cemia will be recorded. Additionally, liver profile and
renal profile will be measured at every visit.
Study outcomes
Primary outcome
The primary outcome of this trial is the changes in
HbA1C.
Secondary outcomes
Secondary outcomes in this study include changes in
other glycemic parameters such as fasting glucose, insulin,
fructosamine, changes in lipid profile (triglyceride, total
cholesterol, HDL-cholesterol, LDL-cholesterol), changes
in inflammation (high-sensitivity C-reactive protein) and
oxidative stress marker (plasma malondialdehyde),
changes in anthropometry parameters (BMI, waist cir-
cumference), changes in metabolite profile (urine, serum),
changes in safety parameters (liver profile and renal
profile), changes in blood pressure, dietary pattern and
physical activity.
Procedure
After obtaining the informed consent, both groups will
be required to attend clinical research center on 4 occa-
sions- baseline, week 4, week 8 (end of study) and week
12 (post study follow-up). Subjects will be interviewed
regarding their socio-demographic background at base-
line. At each follow-up, all subjects will undergo a phys-
ical examination which include anthropometric, blood
pressure, blood test, urine test and completed a dietary
history questionnaire and international physical activity
questionnaire (IPAQ).
Anthropometry measurements including weight,
height and waist circumference will be measured. Body
height will be measured using SECA stadiometer model
217 (SECA, Hamburg, Germany) to the nearest 0.1 cm.
Body weight will be measured using a SECA electronic
scale model 703 to the nearest 0.1 kg (SECA, Hamburg,
Germany). Waist circumference in cm will be assessed
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midway between the lowest rib and the iliac crest using
a non-stretchable tape measure. BMI will be calculated
using World Health Organization classification [30].
Blood pressure will be measured using an automatic
blood pressure monitor (Omron, Kyoto, Japan).
Blood sample will be drawn after an overnight fasting
from the antecubital vein with patients in seated pos-
ition. The volume of blood taken will be 10 ml, collected
in four different pre-chilled tubes. A plain evacuated
blood collecting tube will be used to collect 4 ml blood
for metabolomic analysis. One milliliter will be taken in
potassium oxalate/sodium fluoride tubes for fasting glu-
cose. Another 1 ml blood sample will be taken in tubes
containing ethylenediaminetetraacetic acid (EDTA) for
HbA1C. The remainder 4 ml blood will be collected in
the heparinized tube for other biochemistry parameters.
Blood will be drawn by trained nurses and immediately
placed on ice in the dim light environment. Blood sam-
ple that are collected will be centrifuged at 3000 rpm for
10 min at 4 °C to obtain the serum and plasma. 15 ml
urine samples will be collected in the polyethylene con-
tainers. Blood and urine sample that are collected will be
stored at −80 °C until further analysis.
Biochemical assessments
All assays will be performed using Architect ci8200
analyzer (Abbott Laboratories, USA) except glycated
hemoglobin (HbA1C) and malondialdehyde. Fasting
blood glucose will be performed with a hexokinase-
based method (Abbott Laboratories, USA). HbA1C will
be measured with turbidimetric inhibition immunoassay
method (Roche Diagnostics, Germany) using Cobas
Integra 800 (Roche Diagnostics, Germany). Serum total
cholesterol, triglycerides, high-density lipoprotein (HDL)
cholesterol, and low-density lipoprotein (LDL) choles-
terol levels will be quantified by commercially available
enzymatic assay kits (Abbott Diagnostics, USA). High
sensitivity C-reactive protein will be determined using
the quantitative immunoturbidimetric method. For renal
function test, sodium, potassium and chloride will be de-
termined by potentiometric using solid state ion-
selective electrode, urea will be determined by enzymatic
method and creatinine will be determined using the kin-
etic method. For liver function test, total protein will be
determined using biuret endpoint, albumin will be deter-
mined by direct colorimetric determination, total biliru-
bin will be determined by diazonium salt method
whereas alkaline phosphatase, aspartate aminotransfer-
ase, and alanine aminotransferase will be determined by
the kinetic method. Malondialdehyde will be measured
by thiobarbituric acid reactive substances assay using
UV spectrophotometer (UV-1601, Shimadzu, Japan)
[31]. All biochemical assays will be performed by B. P.
Clinical Lab.
Dietary intake assessment
Dietary intake will be assessed with a dietary history
questionnaire. Patients will be requested to provide
complete food descriptions including food and drinks
(brand names), food preparation (ingredients) and cook-
ing method (such as deep-frying, stir-frying, boiling, gril-
ling, barbecue, roasting, and steaming) as detail as
possible in a week. Pictures of food commonly con-
sumed in Malaysia, together with a set of common
household measurement tools (glass, cup, Chinese rice
bowls, soup bowls, plates, teaspoon and tablespoon) will
be provided to assist subjects in estimating the portion
sizes of the food.
The nutrient analysis will be carried out using Nutri-
tionist Pro™ diet analysis software (version 2.5, Axxya
Systems, USA). This software contains several databases
including Nutrient composition of Malaysian foods and
the United States Department of Agriculture (USDA).
For food items unavailable in Nutritionist Pro diet ana-
lysis software, database will be obtained from Singapore
Food Composition Guide (Health Promotion Board,
2003) and all the nutrients for food items will be manu-
ally added to Nutritionist Pro diet analysis software.
Physical activity levels assessment
International Physical Activity Questionnaire (IPAQ)
will be administered to assess the physical activity level
of the subjects. The items in the IPAQ form consist of
scores on walking, moderate-intensity and vigorous-
intensity activity. The IPAQ’s total score for physical ac-
tivity level will be expressed as metabolic equivalents
per minute (MET-min) per week, sums the duration (in
minutes) and frequency of walking, moderate-intensity
and vigorous-intensity activities. Levels of physical ac-
tivity will be category into low, moderate and high as
per IPAQ criteria [32].
Statistical analysis
All clinical data will be performed using SPSS version 21
for windows (SPSS Inc, Chicago, USA). Data will be
expressed as mean ± SD for continuous parameters, and
percentage for categorical parameters. Normality tests
assessed through Shapiro-Wilk tests will be carried out
on each parameter before analysis. For baseline charac-
teristic, independent t-test will be used to compare the
difference in the study outcomes between the diabetic
treatment and control group. All outcome measure-
ments will be evaluated based on intention-to-treat ana-
lysis using all randomized patients who have attended
the blood test at baseline. Missing data will be imputed
using “last observation carried forward” method. The
comparison within each group will be carried out using
paired t-test, while the changes between the two groups
will be conducted using independent t-test. A p-value of
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less than 0.05 will be considered as significant. Data will
be reported with adherence to the CONSORT 2010
guidelines [33].
NMR Measurements
Thawed 400 μL urine samples will be mixed with
200 μL of a 0.75 M phosphate buffer solution (contain-
ing 0.5 % sodium trimethylsilylpropionate-d4 (TSP)) pre-
pared in D2O and transferred to a 5 mm NMR tube.
Thawed 200 μL blood serum samples will be mixed with
400 μL D2O and transferred to a 5 mm NMR tube. All
1H NMR spectra will be collected on a Varian 500 MHz
NMR spectrometer (Agilent technologies, Santa Clara,
United States) equipped with a 5 mm PFG One NMR
probe. One dimensional(1D) NOESY-Presaturation pulse
sequence for urine and 1D Carr-Purcell Meiboom-Gill
(cpmg) experiment for blood serum will be used. Each
free induction decay (FID) will be collected using a total
of 128 scans with a relaxation delay of 2 s.
Multivariate data analysis for metabolomics study
All 1H NMR spectra will be manually phased, baseline-
corrected and reference to TSP (0.0 ppm) using ACD
software (ACD/Labs, Ontario, Canada). Region contain-
ing water (4.5–5.2 ppm) and TSP (0.0–0.2 ppm) will be
excluded. Each 1H NMR spectra will be segmented in
bins of 0.04 ppm. Urine spectra will be normalized based
on creatinine peak and serum spectra will be normalized
based on the glucose peak area. All binned data will be
imported into SIMCA (Version 14.0, Umetrics, Umea,
Sweden). The binned data will be pareto-scaled prior to
multivariate statistical analysis. Multivariate data analysis
including unsupervised principal component analysis
(PCA), and supervised partial least square discriminant
analysis (PLS-DA) will be performed. PCA will be used
to obtain a general overview of the metabolites and to
detect outliers. PLS-DA will be performed to separate
different groups. The quality of the model will be de-
scribed by the parameter of R2 and Q2 which represent
model fitness and predictive ability. All PLS-DA models
will be validated using the permutation test. An overall
p-value of 0.05 based on the Bonferroni correction will
be used.
Discussion
Type 2 diabetes is a common chronic disease worldwide.
Medicinal plants are gaining tremendous resurgence of
interest among researchers recently because of their
health benefits [14, 34]. C. caudatus is widely consumed
among the local Malays in South East Asia and its po-
tential medicinal benefits have been reported [16]. The
strength of this trial is that, it is the first randomized
controlled trial to determine the effectiveness of C. cau-
datus on the outcomes measurement such as glycemic
status, lipid profile, oxidative stress marker, and inflam-
mation marker which are important parameters in pa-
tients with type 2 diabetes.
To the best of knowledge, there is no established data on
herb-drug interaction of C. caudatus. Therefore, an interim
analysis will be carried out to monitor the safety of con-
suming C. caudatus throughout the study. The results of
this trial will provide clinical evidence on the effectiveness
and safety of C. caudatus supplementation in patients with
type 2 diabetes. Moreover, metabolomics is a powerful tool
to study the altered metabolism, identify short-term
changes in biological fluids and serve as biomarker detec-
tion [26]. Metabolomics approach used in this study will fill
in the gap and provide a better understanding of metabolite
profile following the supplementation of C. caudatus.
Therefore, results from this study will contribute to the
knowledge on the therapeutic effect mechanism of C.
caudatus.
To date, the most commonly used metabolomics tech-
nologies for metabolomics study are nuclear magnetic res-
onance (NMR) spectroscopy, and mass spectrometry
(MS) such as liquid chromatography-MS (LC-MS) and
gas chromatography-MS (GC-MS) [26]. GC-MS and LC-
MS are robust technologies that offer high sensitivity in
metabolites detection [26]. However, both of the tech-
niques have some drawbacks including relatively slower
acquisition time, requires sample derivatization (GC-MS),
consumption of sample (both LC-MS and GC-MS), chro-
matography can drift during a sample run, which makes
data processing difficult (LC-MS), and peak assignment is
a major challenge (LCMS) [35, 36]. On the other hand,
NMR offers some advantages such as its ability to provide
high-resolution spectra, requires relatively simpler sample
preparation hence more rapid analysis and more import-
antly non-destructive of the sample. However, NMR-
based metabolomics has a lower sensitivity compared to
MS [35–37].
We used NMR in this study as NMR-based metabolo-
mics can detect many different metabolites simultan-
eously such as carbohydrate, amino acids, organic and
fatty acids, amines and lipids. In addition, NMR-based
metabolomic have shown high reproducibility and iden-
tification of the metabolites is relatively easy due to a
good library of spectra [36]. The most prominent metab-
olites in the 1H NMR blood serum spectra are fat
(methylene- and methyl-moieties from the lipoproteins),
amino acids, lactate and glucose [38]. Meanwhile,
creatinine, creatine, trimethylamide N-oxide, dimethyla-
mide, citrate and lactate are the most significant metabo-
lites found in the 1H NMR urinary spectra [39]. Recently,
studies have revealed that there is a change in the amino
acid metabolism in addition to the changes in glucose and
fatty acid metabolism in patients with type 2 diabetes .
Raised branched-chain amino acids including leucine,
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valine, isoleucine and glycerol were associated with
the insulin assistance [40]. In the current study,
NMR-based metabolomics is used to investigate the
metabolic perturbation due to C. caudatus supple-
mentation in patients with type 2 diabetes. To com-
plement the current study, future studies involve MS-
based metabolomics would provide further insight
into the fatty-acid profiling in patients with type 2
diabetes.
However, there are limitations in this trial. Placebo is
not used in this study. The reason is because there is
no identical vegetable that can mimic the taste of C.
caudatus. In addition,, there is also no blinding among
the patients because they would know once they allocated
in the treatment arm as they will receive the supplementa-
tion of C. caudatus. Therefore, the possibility of bias can-
not be ruled out. In conclusion, findings from this study
will provide significant evidence of using C. caudatus as
an adjuvant therapy in patients with type 2 diabetes.
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